These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5399 related articles for article (PubMed ID: 3378376)
1. Cross linking of anti-B16 melanoma monoclonal antibodies to lymphokine activated killer (LAK) cells: possible role in the therapy of B16 melanoma. Eisenthal A; Rosenberg SA Clin Exp Metastasis; 1988; 6(5):387-400. PubMed ID: 3378376 [TBL] [Abstract][Full Text] [Related]
2. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases. Eisenthal A; Cameron RB; Uppenkamp I; Rosenberg SA Cancer Res; 1988 Dec; 48(24 Pt 1):7140-5. PubMed ID: 3263900 [TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy. Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431 [TBL] [Abstract][Full Text] [Related]
4. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. Mulé JJ; Yang J; Shu S; Rosenberg SA J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106 [TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types. Papa MZ; Mulé JJ; Rosenberg SA Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517 [TBL] [Abstract][Full Text] [Related]
6. Distinct and non-cross-reactive epitopes are recognized on B16 melanoma by LAK cells and anti-B16 monoclonal antibodies. Tzeng JJ; Barth RF; Johnson CW; Adams DM Proc Soc Exp Biol Med; 1990 Apr; 193(4):285-92. PubMed ID: 1690893 [TBL] [Abstract][Full Text] [Related]
7. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. Mazumder A; Rosenberg SA J Exp Med; 1984 Feb; 159(2):495-507. PubMed ID: 6141211 [TBL] [Abstract][Full Text] [Related]
8. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro. Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994 [TBL] [Abstract][Full Text] [Related]
9. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. Rosenberg SA; Mulé JJ; Spiess PJ; Reichert CM; Schwarz SL J Exp Med; 1985 May; 161(5):1169-88. PubMed ID: 3886826 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma. Gautam SC; Chikkala NF; Lewis I; Grabowski DR; Finke JH; Ganapathi R Anticancer Res; 1992; 12(3):921-5. PubMed ID: 1622150 [TBL] [Abstract][Full Text] [Related]
11. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715 [TBL] [Abstract][Full Text] [Related]
12. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation. Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491 [TBL] [Abstract][Full Text] [Related]
13. Sensitivity of B16 melanoma sublines to lymphokine-activated killer cells as determined by 51Cr-release and clonogenic assays. Tzeng JJ; Barth RF J Immunol Methods; 1990 Apr; 128(2):257-66. PubMed ID: 2324514 [TBL] [Abstract][Full Text] [Related]
14. Augmentation of lymphokine-activated killer cell cytotoxicity by monoclonal antibodies against human small cell lung carcinoma. Tong AW; Lee JC; Wang RM; Ordonez G; Stone MJ Cancer Res; 1989 Aug; 49(15):4103-8. PubMed ID: 2545333 [TBL] [Abstract][Full Text] [Related]
15. Cytotoxic effects on viable human leukemic cells by combinations of lymphokine activated killer cells and monoclonal antibodies. Vasilopoulos G; Sjögren AM; Reizenstein P Leuk Res; 1989; 13(1):87-91. PubMed ID: 2915576 [TBL] [Abstract][Full Text] [Related]
16. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia. Gregg EO; Gregg IC; Green I Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265 [TBL] [Abstract][Full Text] [Related]
17. Adoptive transfer of H-2-incompatible lymphokine-activated killer (LAK) cells: an approach for successful cancer immunotherapy free from graft-versus-host disease (GVHD) using murine models. Toshitani A; Taniguchi K; Himeno K; Kawano Y; Nomoto K Cell Immunol; 1988 Sep; 115(2):373-82. PubMed ID: 3409329 [TBL] [Abstract][Full Text] [Related]
18. Establishment of cell-to-cell contact by adoptively transferred adherent lymphokine-activated killer cells with metastatic murine melanoma cells. Basse PH; Nannmark U; Johansson BR; Herberman RB; Goldfarb RH J Natl Cancer Inst; 1991 Jul; 83(13):944-50. PubMed ID: 2067037 [TBL] [Abstract][Full Text] [Related]
19. Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity. Ting CC; Hargrove ME; Yun YS J Immunol; 1988 Aug; 141(3):741-8. PubMed ID: 3260909 [TBL] [Abstract][Full Text] [Related]